Smoldering Systemic Mastocytosis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Sources

Aliases & Classifications for Smoldering Systemic Mastocytosis

MalaCards integrated aliases for Smoldering Systemic Mastocytosis:

Name: Smoldering Systemic Mastocytosis ⁵⁹

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue

Malignant mast cell tumour

Orphanet: ⁵⁹

Rare haematological diseases

External Ids:

ICD10 via Orphanet ³⁴ C96.2

Orphanet ⁵⁹ ORPHA158775

Sources

Summaries for Smoldering Systemic Mastocytosis

MalaCards based summary : Smoldering Systemic Mastocytosis is related to systemic mastocytosis and mastocytosis. An important gene associated with Smoldering Systemic Mastocytosis is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase). The drugs Cladribine and Antidepressive Agents have been mentioned in the context of this disorder. Affiliated tissues include bone and bone marrow.

Sources

Related Diseases for Smoldering Systemic Mastocytosis

Diseases related to Smoldering Systemic Mastocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

#	Related Disease	Score
1	systemic mastocytosis	10.1
2	mastocytosis	10.1
3	mast-cell leukemia	10.1

Sources

Symptoms & Phenotypes for Smoldering Systemic Mastocytosis

Sources

Drugs & Therapeutics for Smoldering Systemic Mastocytosis

Drugs for Smoldering Systemic Mastocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Cladribine

Approved, Investigational

Phase 3

4291-63-8

20279

Synonyms:

(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol

(2R,3S,5R)-5-(6-amino-2-Chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol

2 Chlorodeoxyadenosine

24757-90-2

2CdA

2-CdA

2-chloro-2'-Deoxyadenosine

2-Chloro-2'-deoxyadenosine

2-chloro-2'-Deoxy-b-adenosine

2-chloro-2'-Deoxy-beta-adenosine

2-Chloro-2'-deoxy-beta-adenosine

2-chloro-2'-Deoxy-β-adenosine

2-chloro-6-amino-9-(2-Deoxy-b-D-erythro-pentofuranosyl)purine

2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine

2-chloro-6-amino-9-(2-Deoxy-beta-D-erythro-pentofuranosyl)purine

2-Chloro-6-amino-9-(2-deoxy-beta-D-erythropentofuranosyl)purine

2-chloro-6-amino-9-(2-deoxy-β-D-erythro-pentofuranosyl)purine

2-chloro-6-amino-9-(2-Deoxy-β-D-erythro-pentofuranosyl)purine

2-chloro-deoxyadenosine

2-chloro-Deoxyadenosine

2-Chlorodeoxyadenosine

2ClAdo

2'-Deoxy-2-chloroadenosine

4291-63-8

AC1L2FXP

AC-7591

Adenosine, 2-chloro-2'-deoxy

BRN 0624220

C10H12ClN5O3.C3H8

CHEBI:567361

CHEMBL1619

Chlorodeoxyadenosine

CID20279

CL9

Cladarabine

Cladaribine

cladribina

Cladribina

cladribine

Cladribine

Cladribine (JAN/USAN/INN)

Cladribine [USAN:INN:BAN]

cladribinum

Cladribinum

CldAdo

CPD000058553

D01370

D017338

DB00242

FT-0080707

HMS2052K13

HSDB 7564

Leustat

Leustatin

Leustatin (TN)

Leustatin, 2-chlorodeoxyadenosine, Cladribine

Litak

LS-15109

MLS000028377

MLS000028484

MLS000759397

MLS001077345

MolPort-002-054-532

MolPort-005-935-074

Movectro

Mylinax

NCGC00022567-05

NCGC00164384-01

NSC 105014

NSC 105014-F

NSC-105014

RWJ 26251

RWJ-26251

RWJ-26251-000

S1199_Selleck

SAM001246526

SMR000058553

UNII-47M74X9YT5

ZINC03798064

2

Antidepressive Agents

Phase 3

3

2-chloro-3'-deoxyadenosine

Phase 3

4

Cromolyn Sodium

Phase 3

5

Histamine Antagonists

Phase 3

6

Histamine H1 Antagonists

Phase 3

7

Proton Pump Inhibitors

Phase 3

8

Interferon-alpha

Phase 3

9

Leukotriene Antagonists

Phase 3

10

interferons

Phase 3

11

midostaurin

Approved, Investigational

Phase 2

120685-11-2

104937 9829523

Synonyms:

120685-11-2

4'-N-benzoylstaurosporine

C411007

CHEMBL338448

CHEMBL608533

CID9829523

CPG 41251

D05029

HMS3229K17

midostaurin

Midostaurin

Midostaurin (USAN/INN)

N-Benzoylstaurosporine

NSC656576

PKC412

PKC-412

RYDAPT

12

Tyrosine

Approved, Investigational, Nutraceutical

Phase 2

60-18-4

6057

Synonyms:

(-)-a-amino-P-Hydroxyhydrocinnamate

(-)-a-amino-P-Hydroxyhydrocinnamic acid

(-)-alpha-amino-P-Hydroxyhydrocinnamate

(-)-alpha-amino-P-Hydroxyhydrocinnamic acid

(-)-alpha-Amino-p-hydroxyhydrocinnamic acid

(-)-α-amino-P-hydroxyhydrocinnamate

(−)-α-amino-p-hydroxyhydrocinnamic acid

(-)-α-amino-P-hydroxyhydrocinnamic acid

(2S)-2-amino-3-(4-Hydroxyphenyl)propanoate

(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid

(2S)-2-amino-3-(4-Hydroxyphenyl)propanoic acid

(S)-(-)-Tyrosine

(S)-2-Amino-3-(4-hydroxyphenyl)propionic acid

(S)-2-amino-3-(P-Hydroxyphenyl)propionate

(S)-2-amino-3-(P-Hydroxyphenyl)propionic acid

(S)-2-Amino-3-(p-hydroxyphenyl)propionic acid

(S)-3-(p-Hydroxyphenyl)alanine

(S)-3-(P-Hydroxyphenyl)alanine

(S)-a-amino-4-Hydroxybenzenepropanoate

(S)-a-amino-4-Hydroxy-benzenepropanoate

(S)-a-amino-4-Hydroxybenzenepropanoic acid

(S)-a-amino-4-Hydroxy-benzenepropanoic acid

(S)-alpha-amino-4-Hydroxybenzenepropanoate

(S)-alpha-amino-4-Hydroxy-benzenepropanoate

(S)-alpha-amino-4-Hydroxybenzenepropanoic acid

(S)-alpha-amino-4-Hydroxy-benzenepropanoic acid

(S)-alpha-Amino-4-hydroxybenzenepropanoic acid

(S)-Tyrosine

(S)-α-amino-4-hydroxybenzenepropanoate

(S)-α-amino-4-hydroxybenzenepropanoic acid

140-43-2

1991-85-1

25619-78-7

2-amino-3-(4-Hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoate

2-amino-3-(4-Hydroxyphen yl)-2-amino-3-(4-hydroxyphenyl)-propanoic acid

2-Amino-3-(p-hydroxyphenyl)propionic acid

2csm

3-(4-Hydroxyphenyl)-L-alanine

3-(p-Hydroxyphenyl)alanine

46209-14-7

4-hydroxy-L-phenylalanine

4-Hydroxy-L-phenylalanine

4ts1

55520-40-6

60-18-4

93829_FLUKA

93829_SIGMA

AB1002647

AC-11295

AC1L1LPI

AC1Q4U7L

AC1Q4U7M

AI3-09055

alpha-Amino-beta-(4-hydroxyphenyl)propionic acid

AR-1J3457

BB_NC-1194

Benzenepropanoate

Benzenepropanoic acid

beta-(p-Hydroxyphenyl)alanine

bmse000051

C00082

CHEBI:17895

CHEMBL925

CID6057

D00022

DB00135

DB03839

DD69927C-C6A8-4BC6-8E9A-0AB423B176E7

DTY

EINECS 200-460-4

FEMA No. 3736

Free-Form L-Tyrosine

HSDB 2003

H-Tyr-OH

L Tyrosine

L-(-)-Tyrosine

L-2-Amino-3-p-hydroxyphenylpropanoic acid

L-p-Tyrosine

L-P-Tyrosine

LS-2336

L-Tyrosin

L-tyrosine

L-Tyrosine (9CI)

L-Tyrosine (JAN)

L-Tyrosine hydrochloride

L-Tyrosine, homopolymer

L-Tyrosine, monomer

Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs

Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide

Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction

Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide

Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours

MolPort-001-792-016

NCGC00159350-02

NCGC00159350-03

nchembio.105-comp1

nchembio.121-comp7

nchembio.186-comp84

nchembio.284-comp7

nchembio816-comp11

NSC 82624

Para tyrosine

Para-tyrosine

p-Tyrosine

P-Tyrosine

Rxosine

T0550

T3754_SIAL

T4321_SIAL

T4321_SIGMA

T8566_SIGMA

tirosina

Tirosina

Tirosina [Spanish]

tyr

Tyr

TYR NH3+ COOH

tyrosine

Tyrosine

TYROSINE

Tyrosine (USP/INN)

Tyrosine (VAN)

Tyrosine [USAN:INN]

Tyrosine Power

Tyrosine, L- (8CI)

Tyrosine, L isomer

Tyrosine, L-isomer

Tyrosinum

Tyrosinum [Latin]

UNII-42HK56048U

W373605_ALDRICH

Y

13

Staurosporine

Experimental

Phase 2

62996-74-1

14

Specific substance maruyama

Phase 2

15

Protein Kinase Inhibitors

Phase 2

16

Angiogenesis Inhibitors

Phase 2

17

Anti-Infective Agents

Phase 2

18

Angiogenesis Modulating Agents

Phase 2

19

Anti-Bacterial Agents

Phase 2

20

Immunosuppressive Agents

Phase 2

21

Immunologic Factors

Phase 2

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	Randomized, Placebo-controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib at 6 mg/kg/Day to Placebo in Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap	Completed	NCT00814073	Phase 3	Masitinib;Placebo
2	Phase II Single Arm Open Pilot Study to Demonstrate the Efficacy of Midostaurin in Symptom Improvement and Decrease of Mast Cell Burden in Patients With Indolent or Smoldering Systemic Mastocytosis.	Unknown status	NCT01920204	Phase 2	Midostaurin,
3	Phase II Study of Thalidomide in Mastocytosis	Completed	NCT00769587	Phase 2	thalidomide
4	A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy	Recruiting	NCT03731260	Phase 2	Avapritinib;Placebo
5	Mast Cell Connect: A Registry for Patients With Mastocytosis	Recruiting	NCT02620254

Search NIH Clinical Center for Smoldering Systemic Mastocytosis

Sources

Genetic Tests for Smoldering Systemic Mastocytosis

Sources

Anatomical Context for Smoldering Systemic Mastocytosis

MalaCards organs/tissues related to Smoldering Systemic Mastocytosis:

⁴¹

Bone, Bone Marrow

Sources

Publications for Smoldering Systemic Mastocytosis

Articles related to Smoldering Systemic Mastocytosis:

#	Title	Authors	PMID	Year
1	Novel approaches to treating advanced systemic mastocytosis. ³⁸	Gilreath JA...Deininger MW	31372066	2019
2	Diagnostic value of tryptase in anaphylaxis and mastocytosis. ³⁸	Schwartz LB	16931288	2006
3	Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. ³⁸	Pardanani A...Tefferi A	15203275	2004
4	["Smoldering systemic mastocytosis. "Successful therapy with cladribine]. ³⁸	Schleyer V...Szeimies RM	15241520	2004

Sources

Genes for Smoldering Systemic Mastocytosis

Genes related to Smoldering Systemic Mastocytosis (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	350	Causative somatic mutation ⁵⁹

Sources

Variations for Smoldering Systemic Mastocytosis

Sources

Expression for Smoldering Systemic Mastocytosis

Search GEO for disease gene expression data for Smoldering Systemic Mastocytosis.

Sources

Pathways for Smoldering Systemic Mastocytosis

Sources

GO Terms for Smoldering Systemic Mastocytosis

Sources

Sources for Smoldering Systemic Mastocytosis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ TGDB

⁷¹ Tocris

⁷² UMLS

⁷³ UMLS via Orphanet

⁷⁴ UniProtKB/Swiss-Prot

⁷⁵ Wikipedia